Innovent Biologics and IASO Bio Strengthen Strategic Collaboration to Advance Innovation in Cell Therapy

According to the terms of the agreement, IASO Bio will purchase the relevant rights owned by Innovent Bio under the original BCMA CAR-T cooperation agreement at the agreed price; meanwhile, Innovent Bio will invest in IASO Bio at the same price, holding 18% of IASO Bio’s shares after the investment. Under the new strategic cooperation framework, both parties will achieve a high level of resource integration in the field of cellular immunotherapy. IASO Bio will obtain Focoso.^®(Idecabtagene Vicleucel Injection) global market commercialization rights and intellectual property licensing, among other rights, and independently handle and make decisions regarding the product's development, production, and sales; meanwhile, Innovent Bio becomes a strategic shareholder of IASO Bio.

Focasu developed by Innovent Bio in collaboration with IASO Bio^®(Idecabtagene Vicleucel Injection) was officially approved for marketing by the National Medical Products Administration (NMPA) on June 30, 2023. It is the world's first commercially available fully human CAR-T product, China's first self-developed and fully self-manufactured CAR-T cell therapy, the first domestically approved BCMA-targeted CAR-T product in China, and the first cell therapy product approved in China for the treatment of multiple myeloma. On March 28, 2024, its Investigational New Drug (IND) application was again approved, intending to expand its indications to treat patients with relapsed/refractory multiple myeloma who have previously undergone 1-2 lines of therapy and are lenalidomide-resistant. In 2024, its IND applications for treating refractory generalized myasthenia gravis (gMG) and other autoimmune diseases were also approved in both China and the United States.

Dr. Dechao Yu, Founder, Chairman and CEO of Innovent Bio"We highly appreciate the professional capabilities, innovative spirit, and high execution demonstrated by IASO Bio in the specialized field of cell therapy. We believe that the new collaborative model will better leverage the synergy of resources from both parties. As a cutting-edge biopharmaceutical product, CAR-T cell therapy benefits greatly from more integrated resources, expertise, and teams, which will fully unlock its potential in manufacturing, indication development, and commercial operations. Meanwhile, as shareholders, we will continue to provide strategic support to IASO Bio. Innovent Bio is committed to advancing the development of the biopharmaceutical industry, and we look forward to working with IASO Bio to improve global patient access to life-saving therapies, bringing hope to more patients."

Ms. Zhang Jinhua, Founder, Chairwoman and Chief Executive Officer of IASO Bio"We sincerely thank Innovent Bio for their high recognition and trust in our R&D capabilities and commercialization expertise. Over the past six years, we have built a solid partnership with Innovent Bio, jointly witnessing each other's innovation and growth in the biopharmaceutical field. As a leading enterprise in China’s innovative drug development, Innovent Bio's outstanding achievements in the biopharmaceutical industry have always been an exemplary model for our pursuit of excellence and continuous learning. We firmly believe that this strategic alliance will bring significant synergies to both parties, fully leverage our respective strengths, and jointly contribute to advancing innovative therapeutic solutions. Staying true to our mission of bringing more innovative therapies to patients, we look forward to achieving mutual success in our future strategic partnership with Innovent Bio."